ExpreS2ion has a streamlined company structure. ExpreS2ion Biotech Holding AB is the Swedish entity listed on Nasdaq First North Growth Market since 2016. ExpreS2ion Biotechnologies ApS is the operational entity, with offices and labs in the Scion DTU Science park 20 km north of Copenhagen, Denmark, and was established in 2010. AdaptVac ApS is a joint venture established in 2017 together with a group of scientists from the Institute of Immunology and Microbiology at the University of Copenhagen. The scientists own their share of AdaptVac through a joint holding company named NextGen Vaccines ApS.
AdaptVac Aps was formed in 2017 as a 50/50 joint venture between ExpreS2ion Biotechnologies ApS and NextGen Vaccines, a University of Copenhagen spin-out. The goal of the Joint Venture is to create a world class unit for the development of highly competitive vaccines and therapeutics against infectious diseases, cancer, and immunological disorders. The combination of ExpreS2ion’s proprietary insect cell expression technology, ExpreS2, and NextGen’s unique expertise in proprietary Virus-Like Particle (VLP) technology makes AdaptVac a strong and versatile player in the field of new vaccines and immune therapy. The Company’s ownership stake in AdaptVac was reduced from 50 percent to 34 percent in February of 2021 upon exercise of the option to in-license the breast cancer vaccine candidate AV001/Her2-cVLP.